Founded in Barcelona in 2023, Disrupt Therapeutics is a biotech company dedicated to pioneering solutions for cannabis use disorder (CUD), addressing this critical unmet need.
Our lead candidate, DRT-101, is an oral treatment aimed at reducing harmful cravings and cognitive impairments associated with cannabis use.
We are dedicated to advancing DRT-101 from the preclinical stage into clinical trials to substantially improve patient lives.
At the core of our research is the recent finding that the cannabinoid CB1 receptor can form heterodimer complexes with the serotonin 5HT2A receptor (CB1R-5HT2AR) in the CNS, an interaction linked to cannabis addiction and cognitive impairment.
Our innovative proposal, DRT-101 (WO/2021/064165, PCT/EP2020/077642), is a fully druggable, peptide-based medication specifically designed to disrupt the CB1R-5HT2AR heterodimer. Through this targeted mechanism, DRT-101 aims to prevent the addictive and cognitive effects of both recreational and medical cannabinoid use.
Dr. Aiguader, 88
Barcelona Biomedical Research Park
08003 Barcelona (Spain)
info@disrupttherapeutics.com
Copyright © 2025 Disrupt Therapeutics.
